More than one-third of the worldwide population is overweight or obese and therefore at risk
of developing type 2 diabetes mellitus. In order to mitigate this pandemic, safer and more …

Islet amyloid polypeptide (IAPP, or amylin) is one of the major secretory products of β-cells of
the pancreatic islets of Langerhans. It is a regulatory peptide with putative function both …

Type 2 diabetes (T2D) is a highly prevalent and chronic metabolic disorder. Recent
evidence suggests that formation of toxic aggregates of the islet amyloid polypeptide (IAPP) …

Type 2 diabetes is characterized by impaired insulin secretion. Some but not all studies
suggest that a decrease in β-cell mass contributes to this. We examined pancreatic tissue …

Amyloid deposition and reduced β-cell mass are pathological hallmarks of the pancreatic
islet in type 2 diabetes; however, whether the extent of amyloid deposition is associated with …

Islet amyloid deposition is a pathogenic feature of type 2 diabetes, and these deposits
contain the unique amyloidogenic peptide islet amyloid polypeptide. Autopsy studies in …

Islet amyloid has been recognized as a pathological entity in type 2 diabetes since the turn
of the century. It has as its unique component the islet beta-cell peptide islet amyloid …

Pancreatic amyloid is found in more than 95% of type II diabetes patients. Pancreatic
amyloid is formed by the aggregation of islet amyloid polypeptide (hIAPP or amylin), which is …

Nondiabetic obese humans adapt to insulin resistance by increasing β-cell mass. In
contrast, obese humans with type 2 diabetes have an∼ 60% deficit in β-cell mass. Recent …

Due to the high prevalence of diabetes worldwide, extensive research is still being
performed to develop new antidiabetic agents and determine their mechanisms of action …